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Background-—Pediatric-onset restrictive cardiomyopathy (RCM) is associated with high mortality, but underlying mechanisms of
disease are under investigated. RCM-associated diastolic dysfunction secondary to variants in TNNT2-encoded cardiac troponin T
(TNNT2) is poorly described.
Methods and Results-—Genetic analysis of a proband and kindred with RCM identified TNNT2-R94C, which cosegregated in a
family with 2 generations of RCM, ventricular arrhythmias, and sudden death. TNNT2-R94C was absent among large, population-
based cohorts Genome Aggregation Database (gnomAD) and predicted to be pathologic by in silico modeling. Biophysical
experiments using recombinant human TNNT2-R94C demonstrated impaired cardiac regulation at the molecular level attributed to
reduced calcium-dependent blocking of myosin’s interaction with the thin filament. Computational modeling predicted a shift in the
force-calcium curve for the R94C mutant toward submaximal calcium activation compared within the wild type, suggesting low
levels of muscle activation even at resting calcium concentrations and hypercontractility following activation by calcium.
Conclusions-—The pathogenic TNNT2-R94C variant activates thin-filament–mediated sarcomeric contraction at submaximal
calcium concentrations, likely resulting in increased muscle tension during diastole and hypercontractility during systole. This
describes the proximal biophysical mechanism for development of RCM in this family. ( J Am Heart Assoc. 2020;9:e015111. DOI:
10.1161/JAHA.119.015111.)
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R estrictive cardiomyopathy (RCM) is a primary disorder ofincreased myocardial stiffness and diastolic dysfunction
with often normal to slightly hypertrophied ventricular wall
thickness.1This disease typically manifests with marked atrial
dilation, attributable to transmission of elevated pressures
during ventricular relaxation, with preserved ventricular sys-
tolic function. The etiologies of RCM are broad, including
inherited and acquired causes, and the prognosis is poor.2,3
RCM comprises one of a group of primary muscle diseases of
the heart collectively called cardiomyopathies. Once thought
to be separate entities, cardiomyopathies are now thought to
be a spectrum of diseases with the presence of restrictive and
hypertrophic features varying across the phenotypes. Hyper-
trophic cardiomyopathy (HCM) is common and is associated
with mutations in sarcomere protein-encoding genes.4–7 RCM
and HCM patients often share the feature of diastolic
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dysfunction, and a subset of patients with RCM demonstrate
mild ventricular hypertrophy. The genetic mechanisms under-
lying RCM, corresponding clinical phenotypes, and subclass of
RCM with hypertrophic features have not been well described.
To date, >1000 variants associated with cardiomyopathy
have been identified in sarcomeric genes, including TNNT2-
encoded cardiac troponin T (TNNT2).7,8 TNNT2 combines with
the calcium-binding proteins troponin C and troponin I to form
the troponin complex. This troponin complex is integrated
into the thin filament of the sarcomere and, in combination
with tropomyosin, coordinates contraction of the cardiac
muscle by regulating the calcium-dependent interaction
between myosin and the thin filament. TNNT2-specific gene
variants are a known, rare cause of HCM, found in 3% to 5% of
patients with HCM.9 They have also been associated with the
development of ventricular arrhythmias.10–13 Recent studies
have suggested that variants in TNNT2 may also be associ-
ated with development of RCM.14–16 For example, the TNNT2
variant, I79N, has been shown to cause RCM and HCM within
the same family.17 Previous biochemical studies have sug-
gested that TNNT2 variants identified in patients with HCM
and dilated cardiomyopathy result in alterations in calcium
sensitivity, leading to systolic dysfunction.18,19 Based on
these findings, this molecular mechanism has been extrapo-
lated to disorders of diastolic dysfunction. To confirm this
hypothesis, variants known to produce a clinical phenotype of
primary diastolic dysfunction and RCM should be studied to
confirm the underlying molecular mechanisms.
Herein, we identify a TNNT2 variant, TNNT2-R94C, in a
family with multiple members affected with a range of clinical
presentations, including arrhythmias, cardiomyopathy with
predominantly restrictive physiology, and sudden death. We
used biochemical techniques and computational modeling to
demonstrate that this variant is likely pathogenic, and we
determined its molecular mechanism. We show that this
variant causes activation of the thin filament at submaximal
calcium concentrations, contributing to diastolic dysfunction
as observed in this family.
Methods
The data that support the findings of this study are available
from the corresponding author upon reasonable request.
Clinical Evaluation
This study received approval from the institutional review
boards at Baylor College of Medicine and Duke University
Health System. Available clinical data from the identified
proband and relatives were collected, which included perti-
nent personal and family history, physical examination,
standard 12-lead ECG analysis, echocardiographic testing,
cardiac catheterization data, and genetic testing. An autopsy
was performed on the brother of the proband by the Medical
Examiner Service of the Harris County, Texas, Institute of
Forensic Sciences (Houston, TX) following his death. The
family underwent a full evaluation by pediatric cardiomyopa-
thy and heart failure specialists.
Genetic Analysis
The proband underwent clinical genetic testing using the
Famillion (New Haven, CT) HCM panel test, which involves
sequencing 9 sarcomeric genes (ACTC, MYBPC3, MYH7, MYL2,
MYL3, TNNT2, TNNI3, TNNC1, and TPM1) and 3 metabolic
genes (GLA, LAMP2, and PRKAG2). Clinical genetic testing was
performed on family members using the same HCM panel test.
Subsequently, Sanger sequencing was utilized for confirmatory
testing. For this, genomic DNA was isolated using the Gentra
Puregene Blood Kit (Qiagen, Valencia, CA) from peripheral
whole blood as well as postmortem blood spot. To confirm the
absence of the identified presumed pathogenic variant in
ostensibly healthy individuals, the publicly available Genome
Aggregation Database (gnomAD) was used as a control cohort,
which is comprised of a total of 15 708 genomes and 125 748
exomes from 141 456 individuals.20 Though the gnomAD
database is comprised partly of various disease-specific
cohorts in addition to population genetics studies, it excludes
individuals known to have severe pediatric disease or severe
disease in their first-degree relatives. These individuals were
therefore utilized as “control” or “reference” alleles. Variant
Clinical Perspective
What Is New?
• TNNT2-encoded cardiac troponin T TNNT2-R94C is a heritable
cause of restrictive cardiomyopathy and sudden death.
• This pathologic variant leads to initiation of cardiac muscle
contraction at resting calcium levels.
• Computational modeling predicts that this causes increased
basal muscle tension and likely leads to diastolic cardiac
dysfunction.
What Are the Clinical Implications?
• Pediatric restrictive cardiomyopathy is a rare cause of
sudden cardiac death in children.
• This study demonstrates the pathological mechanism of the
TNNT2-R94C variant.
• Patients with this variant should be followed closely for
development of cardiomyopathy and/or arrhythmias, and
familial screening should be performed when the variant is
discovered in an individual.
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pathogenicity classification was also assigned based on 2015
American College of Medical Genetics criteria21 and ClinVar
(National Center for Biotechnology Information).22
Sequencing Conservation
Sequence conservation analysis was performed using the
primary TNNT2 sequence obtained from the National Center
for Biotechnology Information (NP_001001430.1).23 Multal-
ign alignment algorithms were utilized to determine sequence
conservation across species.24,25
In Silico Variant Pathogenicity Modeling
In silico variant pathogenicity prediction was performed using
GenMAPP,26 PolyPhen-2,27 PredictSNP,28 SIFT,29 SNAP,30 and
PANTHER31 prediction tools. Variants were considered
pathogenic if they carried the designation of “damaging or
probably damaging,” “deleterious,” “disease-related,” and/or
“disease-associated.” Variants were considered benign if they
carried designation of “tolerated,” “benign,” or “neutral.”
Purification of Cardiac Myosin and Actin
Porcine cardiac ventricular myosin and actin were purified
from cryoground tissue as previously described.32–34 Myosin
subfragment 1 was prepared by chymotrypsic digestion as
previously described,32 using standard techniques,35,36 and
the purity of the protein was assessed by SDS-PAGE. The
concentration of myosin subfragment 1 was determined by
absorbance at 280 and 320 nm. Pyrene-labeled actin was
prepared from acetone powder37 and labeled with the dye,
N-(1-pyrenyl)iodoacetamide (pyrene), as described previ-
ously.38,39 Concentration of pyrene actin was determined by
absorbance at 290 and 344 nm. Before use, all actin was
stabilized by incubating with equimolar concentrations of
phalloidin.
Preparation of Recombinant Human Troponin and
Tropomyosin
Human cardiac tropomyosin was expressed in BL21-Codon-
Plus cells (Agilent Technologies, Santa Clara, CA) and purified
using established protocols.32,33,40,41 On the day of the
experiment, tropomyosin was reduced in 50 mmol/L of DTT
at 56°C for 5 minutes, and aggregates were subsequently
removed by ultracentrifugation at 436 000g in an Optima
MAX-TL Ultracentrifuge (Beckman Coulter, Brea, CA).42 The
R94C variant was introduced into TNNT2 using the Quick-
Change Site-Directed Mutagenesis kit (Agilent Technologies).
Human troponins I, T, and C were expressed in BL21-
CodonPlus cells (Agilent Technologies), purified, and com-
plexed using established protocols.43
Determination of KB Using Stopped Flow
Transient Kinetics
To determine the equilibrium constant between the blocked
and closed states, KB, a stopped flow approach developed by
McKillop and Geeves32,44 was utilized. This method analyzes
the rate of myosin binding to reconstituted thin filaments in
the presence and absence of calcium. Pyrene-actin was
excited at 365 nm, and fluorescence emission was detected
using a 390 nm long-pass filter. Reconstituted thin filaments
(5 lmol/L of phalloidin-stabilized pyrene actin, 2 lmol/L of
tropomyosin, and 2 lmol/L of troponin) and 0.04 U/mL of
apyrase were rapidly mixed with 0.5 lmol/L of subfragment
1 myosin and 0.04 U/mL of apyrase at 20°C in an SX-20
stopped flow apparatus (Applied Photophysics, Leatherhead,
UK). The high calcium (pCa 4) buffer contained 200 mmol/L
of KCl, 5 mmol/L of MgCl2, 60 mmol/L of MOPS, 2 mmol/L
of EGTA, 1 mmol/L of DTT, and 2.15 mmol/L of CaCl2. The
low calcium (pCa 9) buffer contained 200 mmol/L of KCl,
5 mmol/L of MgCl2, 60 mmol/L of MOPS, 2 mmol/L of
EGTA, 1 mmol/L of DTT, and 5.2 lmol/L of CaCl2. Myosin
strong binding to pyrene-labeled actin in reconstituted thin
filaments quenches pyrene fluorescence. Fluorescence tran-
sients were collected for at least 3 separate mixes, and a
single exponential function was fit to the transient. KB is
calculated from the ratio of the rates of myosin binding to the
reconstituted thin filaments at high and low calcium44:
kobsðCa2þÞ
kobsðþCa2þÞ
 KB
1þ KB (1)
The average KB was calculated from 3 different experi-
ments, and the P value was calculated from a 2-tailed Student
t test.
Determination of KW, KT, and n From
Fluorescence Titrations
Values of the equilibrium constant between the open and
weakly bound myosin states, KW, the equilibrium constant
between the closed and open states KT, and the size of the
cooperative unit (ie, the number of binding sites on the thin
filament opened by myosin binding), n, were determined by
measuring the steady-state binding ofmyosin to pyrene-labeled
regulated thin filaments.44 Fluorescence titrations were carried
out at 20°C in an Applied Photophysics SX-20. Myosin S1 was
added at 1-minute intervals to a stirred cuvette containing
0.5 lmol/L of pyrene-actin, 0.27 lmol/L of troponin, and
tropomyosin up to a final concentration of 10 lmol/L of
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subfragment 1. Buffers contained 200 mmol/L of KCl,
5 mmol/L of free MgCl2, 60 mmol/L of MOPS, 2 mmol/L of
EGTA, 1 mmol/L of DTT, and 2 mmol/L of ADP and the desired
free concentration of free calcium. Any contaminating ATP was
eliminated by adding 50 lmol/L of P1,P5-di(adenosine-50)
pentaphosphate, 2 mmol/L of glucose, and 1 lmol/L of
hexokinase. Titrations were performed at 3 calcium concen-
trations: low (2 mmol/L of EGTA), intermediate (pCa 6.25), and
high (pCa 3). Five technical replicates were performed. Data
was analyzed as previously described.32
To quantify differences in myosin binding of the wild-type
(WT) and mutant proteins, titration curves were fit to the
fractional change in the fluorescence, a, as a function of
myosin, [M], given by:
a ¼ F0  F
F0  F1 ¼
KW M½ Pn1 KT 1þ KSð Þnþ1ð Þ
KTPn þ Qn þ 1KB
 
1þ KSð Þn1
(2)
where F is the measured fluorescence, F0 is the fluorescence
of the pyrene in the absence of myosin binding, F∞ is the
fluorescence at saturating myosin concentrations, n is the
size of the cooperative unit, P=1+KW[M](1+KS), and
Q=1+KW[M].
44 For the fitting, the equilibrium constant
between the closed and open states (KT), the equilibrium
constant between the open and myosin weakly bound state
(KW), and n were fitted parameters. Titration curves were
globally fit to extract parameter values, 95% CIs by boot-
strapping simulations, and P values were determined as
described.32 KB was fixed based on stopped flow experiments.
The equilibrium constant between the states in which myosin
is weakly and strongly bound to the thin filament (KS) was
fixed based on previous studies.45
Computational Modeling of the Variants on Thin
Filament Regulation
To quantitatively model the impacts of the variant on overall
calcium-force production relationship in the heart, we utilized
a computational model developed by the McCulloch labora-
tory, which uses the measured equilibrium constants to
calculate the expected force per sarcomere as a function of
calcium.46 Model parameters for the mutant protein were
adjusted to be proportional to our measured parameters, and
we used these parameters to simulate a force-calcium curve.
For the WT protein, we used the default model parameters.
Statistical Analysis
A Student t test was performed to determine statistical
significance between 2 groups. P<0.05 was considered
significant, unless otherwise noted.
Results
Clinical Evaluation
The proband is a 2-year-old white girl who was found to have
RCM following an evaluation precipitated by the sudden death
of her older brother. Her ECG demonstrated criteria for right
and left atrial enlargement with marked repolarization abnor-
mality. Echocardiogram revealed mild right atrial and severe
left atrial enlargement (left atrial volume, 61.5 cc/m2; normal,
16–28), with mildly increased left ventricular mass and
otherwise normal ventricular dimensions. Right and left
ventricular systolic function was preserved. These findings
were consistent with a mild form of HCM with markedly
restrictive physiology (Figure 1A and 1B). The proband
suffered a cardiac arrest during phlebotomy and was unable
to be resuscitated.
Her seemingly healthy 4-year-old brother presented with a
sudden cardiac arrest while running on a soccer field and could
not be resuscitated. Autopsy revealed mild cardiomegaly (heart
weighed 147 g; normal, 55–121) with mild biventricular
hypertrophy (left ventricular free wall 0.8 cm (echocardio-
graphic Z-Score, +3.53), interventricular septum 0.9 cm
(echocardiographic Z-Score, +4.78), and right ventricular free
wall (0.3 cm) with myocyte hypertrophy and disarray found on
histopathological examination.47,48 These findings were deter-
mined to be consistent with a diagnosis of HCM, which was
identified as the cause of death. Significant left ventricular
outflow tract obstruction was not present. No genetic testing
was performed at the time of death. Because of this diagnosis,
clinical evaluation of the family was conducted, which included
phenotypic screening and genetic testing.
The proband’s father is a 35-year-old male who was found
to have episodes of asymptomatic, nonsustained ventricular
tachycardia and premature ventricular beats on event mon-
itoring in the setting of normal biventricular size and systolic
function. Cardiac magnetic resonance imaging demonstrated
normal myocardium and marked right and left atrial enlarge-
ment, consistent with diastolic dysfunction and RCM (Fig-
ure, 1C through 1E).
Genetic Evaluation
Cardiomyopathy-based panel testing (Familion; Transgenomic,
Inc., New Haven, CT) was conducted on the proband,
demonstrating a single, heterozygous, variant TNNT2-R94C
(c.280C>T). No other variants were identified in other
cardiomyopathy-associated genes. This variant was absent
in gnomAD and localized to a highly conserved portion of the
N-terminal domain near the tropomyosin binding site (Fig-
ure 2A and 2B). To test whether this variant was found among
all affected individuals, family history was expanded, and a
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total of 8 kindred were consented and subjected for
confirmatory genetic testing. In addition to the proband
(IV.3), postmortem genetic testing of the deceased brother
(IV.2) also demonstrated presence of the heterozygous
TNNT2-R94C variant. While a first trimester fetal death
(IV.4) was also identified from the mother (III.4), no fetal
tissue was available for genetic analysis. The father (III.3) was
also found to carry the TNNT2-R94C, which was absent in
both paternal grandparents (II.1 and II.2) and paternal sibling
(III.2), suggesting a de novo variant that was subsequently
passed in an autosomal-dominant fashion. This is summarized
in Figure 3. In silico prediction modeling was performed and
demonstrated a prediction of deleterious impact from 5 of 6
models and neutral from 1 model, with an average confidence
of 74.6% (Tabl). This variant was designated as pathologic in
ClinVar, and there is strong evidence of pathogenicity based
on 2015 American College of Medical Genetics criteria21 for
classifying pathogenic variants.
R94C Destabilizes the Blocked State of
Tropomyosin and Increases the Equilibrium
Constant for Myosin Weak Binding to the Thin
Filament
Cardiac troponin T is part of the machinery that regulates the
calcium-dependent interactions between myosin and the thin
filament (Figure 4A). To determine the molecular conse-
quences of the TNNT2-R94C variant on cardiac contractile
regulation, we expressed human WT (TNNT2WT) and mutant
troponin (TNNT2R94C) and determined the biochemical
impacts on thin filament regulation.
The first step in muscle activation is the calcium-induced
change in positioning of tropomyosin along the thin filament,
moving it from the blocked to the closed state. The
equilibrium constant that defines this transition, KB, was
calculated by measuring the rate of myosin binding to
reconstituted thin filaments containing pyrene-labeled actin
at high- and low-calcium concentrations.32,44 The pyrene
fluorescence is quenched upon myosin binding, and the rate
of myosin binding to the thin filament can be calculated by
fitting an exponential function to the fluorescence transient
(Figure 4B). In TNNT2WT, the rate of binding at high calcium
(pCa 4) is faster than at low calcium (pCa 9) given that the
blocked state is scarcely populated at high calcium. Whereas
the fluorescence transients collected at high calcium are
similar for the TNNT2WT and TNNT2R94C, at low calcium,
TNNT2R94C binds faster than the TNNT2WT, consistent with
less inhibition at low calcium in TNNT2R49C. Consistent with
this notion, we found that KB for TNNT2
R94C (0.670.17) is
significantly larger than KB for the WT (0.400.15; P=0.04).
This result demonstrates that the inhibitory blocked state is
less populated in TNNT2R94C at low calcium compared with
A B
D EC
Figure 1. Clinical evaluation of TNNT2-R94C–positive kindred. (A) Representative ECG obtained from the proband demonstrating right and left
atrial enlargement with nonspecific ST and T-wave abnormalities and ST depression in the inferolateral leads. An enlarged representative ECG is
shown. (B) Representative echocardiographic images in the parasternal long axis and apical 4-chamber windows demonstrating severe left atrial
enlargement. (C) Cardiac telemetry demonstrating ventricular tachycardia overtaking sinus rhythm. (D) Representative echocardiographic
images from the father of the proband in the parasternal short-axis view demonstrating normal LV size and systolic function. (E) Representative
cardiac MRI images demonstrating right and left atrial enlargement with normal biventricular size and function. LV indicates left ventricular; MRI,
magnetic resonance imaging; TNNT2, TNNT2-encoded cardiac troponin T.
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the TNNT2WT. This loss of inhibition at low calcium would lead
to hypercontractility (ie, increased population of force-
generating states) and create a predisposition toward
myocardial stiffness and ultimately diastolic dysfunction.
Next, we examined the effects of TNNT2R94C on the closed,
open, and myosin-bound states of the thin filament (Fig-
ure 4A) by performing steady-state titrations of myosin
binding to reconstituted pyrene-labeled thin filaments at high
(pCa 3), low (2 mmol/L of EGTA), and intermediate calcium
concentrations (pCa 6.25)32,44 (Figure 4C and 4D). Qualita-
tively, the myosin binding isotherms for the TNNT2WT and
TNNT2R94C thin filaments are similar at high and intermediate
calcium concentrations; however, at low calcium, myosin
binding to TNNT2R94C thin filaments is increased at low
myosin concentrations compared with TNNT2WT. These
findings are consistent with the stopped flow data showing
less inhibition to myosin binding at low calcium. Fitting of the
data (see Table S1 for details) demonstrates that TNNT2R94C
has an increased equilibrium constant for myosin weak
binding, KW (0.20 0.03/+0.16 for TNNT2R94C versus 0.13
0.01/+0.01 for the WT; P=0.002). The variant does not
significantly change the equilibrium constant between the
closed and open states. This includes KT, (0.11 [0.08, 0.12]
for TNNT2R94C versus 0.06 [0.03, 0.06] for the WT at low
calcium, P=0.43; 0.07 [0.04, 0.05] for TNNT2R94C versus
0.08 [0.04, 0.04] for the WT at intermediate calcium,
P=0.45; and 0.14 [0.08, 0.09] for TNNT2R94C versus 0.18
[0.07, 0.08] for the WT at high calcium, P=0.37). Further-
more, cooperativity of activation was unchanged between
TNNT2R94C versus TNNT2WT, n (4.47 [1.66, 2.18] for
TNNT2R94C versus TNNT2WT; P=0.18). These results are
summarized in Figure 5A and 5B.
A B
Figure 2. R94C localizes to a highly conserved region of TNNT2. (A) Sanger sequencing chromatograms of heterozygous mutant TNNT2-R94C
(obtained from subject III-3) and wild-type genotypes. (B) The topological map of TNNT2 with primary sequence alignment from multiple
divergent species is shown. The variant localizes to the N-terminal segment of TNNT2 in the tropomyosin binding domain I. This region is highly
conserved across species. AH indicates actin helix; BD, binding domain; TnC, troponin C; TnI, troponin I; TNNT2, TNNT2-encoded cardiac
troponin T; WT, wild type.
DOI: 10.1161/JAHA.119.015111 Journal of the American Heart Association 6
TNNT2-R94C in Restrictive Cardiomyopathy Ezekian et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on A
pril 3, 2020
Computational Modeling Reveals
Hypercontractility in TNNT2R94C
These biochemical experiments identified the primary effects
of TNNT2R94C on thin filament regulation as 2-fold increases in
the values for both KB and KW. Computational modeling was
used to predict how these changes in equilibrium constants
would affect the force-calcium curve in cardiac muscle.46
Modeling demonstrates a shift in the force-pCa curve for
TNNT2R94C toward submaximal calcium activation compared
with TNNT2WT, consistent with molecular hypercontractility.
The model also predicts that even at resting calcium
concentrations (100–150 nmol/L49,50), there could be some
basal level of activation with TNNT2R94C (Figure 5C). Taken
together, these data demonstrate that TNNT2R94C would yield
less calcium-induced inhibition to contraction, leading to
hypercontractility and potentially an increase in basal muscle
tension. These contractile defects could lead to diastolic
dysfunction, culminating in restrictive cardiac physiology.
Discussion
Spectrum of Cardiomyopathy Phenotypic
Presentation
Recent advances in high-throughput sequencing have facili-
tated the identification of a number of novel cardiomyopathy-
Figure 3. Pedigree of TNNT-R94C kindred. Four generationswere evaluated (denoted by roman numerals). Clinical presentations are noted in red.
The predominant phenotype is an RCM with mild hypertrophic features. Arrow denotes the proband (IV.4). Circles denote female, and squares
denote male. Black fill denotes diagnosis of cardiomyopathy. Gray fill denotes fetal demise (IUFD). White fill denotes no cardiac diagnosis either
following clinical evaluation or by reported history. +/ denotes heterozygosity for TNNT2-R94C variant whereas/ denotes wild type. Diagonal
line denotes deceased. HCM indicates hypertrophic cardiomyopathy; IUFD, intrauterine fetal demise; LVH, left ventricular hypertrophy; RCM,
restrictive cardiomyopathy; SCD, sudden cardiac death; TNNT2, TNNT2-encoded cardiac troponin T; VT, ventricular tachycardia.
Table. In Silico Variant Prediction Aggregate Analysis of the
TNNT2 Arg94Cys Variant Using Variant Prediction Models
Tool Algorithm
Clinical
Significance
Confidence
(%)
GenMAPP Pathway analysis tool Deleterious 72
PolyPhen-2 Na€ıve Bayes classification Deleterious 81
PredictSNP Metaserver Deleterious 76
SIFT Sequence conservation Deleterious 79
SNAP Neural networks Neutral 50
PANTHER Ontology association Deleterious 65
GenMAPP indicates gene map annotator and pathway profiler; PANTHER, protein
analysis through evolutionary relationships; PolyPhen-2, polymorphism phenotyping v2;
SIFT, sorting intolerant from tolerant.
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associated genes, with the number identified as pathogenic
increasing significantly over the last few years.9 Because of
the increased utilization of this technology, it is now possible
to identify shared genetic variants among phenotypically
dissimilar individuals, whose clinical presentations have not
previously been associated with specific genes.51 This has
increased understanding of the role of genetic variants in the
predisposing pathophysiological mechanisms of atypical
forms of cardiomyopathy.52 Here, we describe a variant
associated with relatively mild hypertrophy and clear evidence
of restrictive physiology consistent with RCM. It is well
established that cardiomyopathic diseases, including RCM,
have variable expressivity of disease frequently yielding a wide
spectrum of phenotypes.53,54 This study is supportive of these
previous findings.
We report on a family in which a single variant in TNNT2 is
associated with restrictive cardiomyopathy and sudden cardiac
death. The TNNT2-R94C variant was not observed in control
populations and was predicted to be deleterious by in silico
modeling, ClinVar, and current American College of Medical
Genetics guidelines. Our biochemical data show a clear
molecular phenotype that would be consistent with hypercon-
tractility and diastolic dysfunction, supporting the concept that
this variant is causative for the disease. There are a total of 5
previous reports of the TNNT2-R94C variant (National Center
for Biotechnology Information ClinVar database), all with the
designation of “pathogenic” or “likely pathogenic” and associ-
ated with familial HCM.13,55–58 There has only been 1 previous
report of a TNNT2 variant causing restrictive physiology by
autosomal-dominant inheritance.13 Although the TNNT2-R94C
variant has been previously associated with HCM, the spectrum
of phenotypic features associated with TNNT2-R94C, including
RCM, has not been well described.
Contractile Defects Caused by the R94C Variant
Overall, the clinical phenotype of RCM consists of severe
diastolic dysfunction leading to atrial enlargement and, at
most, mild ventricular hypertrophy. The molecular mecha-
nisms of contractile defects causing diastolic disease remain
largely unknown. Reflecting this, genetic causes of pediatric
RCM cases remain unexplained, with only rare patients
hosting variants within the thin filament. Here, we put forward
TNNT2-R94C as a likely causative of disease. TNNT2 is part of
the troponin complex that regulates calcium-dependent
interactions between the molecular motor myosin and thin
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Figure 4. Measurement of the biochemical steps involved in thin filament activation. (A) Kinetic scheme for thin filament activation.
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both on calcium and myosin binding. Myosin binds weakly to the thin filament before undergoing an isomerization to the strong-binding state,
where force is generated. (B) Measurement of KB, the equilibrium constant between the blocked and closed states, was measured by rapidly
mixing myosin with pyrene-labeled thin filaments at low (pCa 9) and high calcium (pCa 4). Myosin binding quenches fluorescence. The ratio of
the rates of binding at high and low calcium can be used to calculate KB (see Methods). There is significantly less blocking in the R94C mutant
than the WT at low calcium, as evidenced by the faster binding of the mutant at low calcium. (C and D) Equilibrium titrations of myosin with
pyrene-labeled regulated thin filaments enable the calculation of several equilibrium constants (see Methods). Experiments were conducted with
thin filaments containing either (C) TNNT2WT or (D) TNNT2R94C. TNNT2 indicates TNNT2-encoded cardiac troponin T.
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filament. R94 is located in the highly conserved region of the
TNNT2 N-terminal segment, and it is located near other
residues that have been associated with other forms of
cardiomyopathy, such as R92.59–64 Currently, there is no high-
resolution molecular structure of the thin filament or this
region of TNNT2, so it is not possible to determine the exact
structural basis of the biophysical changes that we observe;
however, it has been proposed that this region plays an
important role in mediating interaction between tropomyosin
and the troponin complex. HCM variants in this region have
been associated with reduced affinity of troponin for
tropomyosin,65,66 leading to the proposal that variant-induced
changes in this affinity could reduce the ability of troponin to
regulate interactions between myosin and the thin filament.65
Our data, showing destabilization of the blocked state, would
be consistent with this concept.
Previous analyses of the biochemical effects of HCM-
associated TNNT2 mutations at the R94 position have
demonstrated that appropriate calcium regulation is critical
to normal function of the troponin complex.18,19 Based on
these findings, calcium sensitization is hypothesized to have a
direct impact on cardiac systolic function, with calcium
desensitization likely leading to decreased systolic function
and calcium sensitization likely leading to increased systolic
function. The described R94C variant is novel in that it
produces a clinical phenotype of RCM and primarily diastolic
dysfunction, making it an optimal variant for biochemical
studies to investigate the interaction between calcium
sensitivity and diastolic dysfunction.
Our computational modeling predicts that the R94C variant
will lead to submaximal calcium activation and possibly an
increase in basal tension during diastole. Previous studies of
many HCM variants have demonstrated similar shifts toward
submaximal calcium activation, leading to the proposal that
these variants cause net hypercontractility and diastolic
dysfunction. The phenotype observed in R94C patients,
consisting of a primarily restrictive phenotype with mild
hypertrophy, would be consistent with this hypothesis.
Limitations
Although we illustrate a novel genetic cause of RCM, our
findings are based around a single family and may limit study
generalizability. Our classification of this variant as causative
for the disease is supported by our biochemical studies
demonstrating that the introduction of this single point variant
alone causes hypercontractility and features of diastolic
dysfunction at the molecular scale. Further studies are
warranted to determine how the findings presented here
translate to cellular and organ levels; however, our study
clearly identifies the initial lesion that leads to downstream
changes with disease progression. Clinical genetic testing for
patients with cardiomyopathic disease is routinely limited to
genes of the sarcomere and metabolism, which are known
causes of cardiomyopathy. It is possible that another variant
or variants may be contributing to the severe phenotype
observed in the family. This is unlikely, considering that the
results of our biochemical experiments clearly demonstrate a
pathological mechanism of disease.
Moreover, caution should be used when extrapolating the
results here to the disease progression observed in human
patients. Our biochemical experiments and modeling were
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performed using all mutant troponin; however, most patients
with the disease are heterozygous for the variant, and the
exact proportion of protein that is expressed and incorporated
into the sarcomere can vary with the variant. Moreover, as the
disease progresses, there are changes in gene expression,
fibrosis, and cellular organization that occur over the course
of years. Although our modeling cannot capture the full
complexity of the disease progression, it clearly demonstrates
the initial contractile defects that lead to the disease
phenotype. Future studies will be needed to identify the
connection between the initial defect and disease phenotype
observed in patients in the later stages of the disease.
Conclusions
The R94C variant in TNNT2 is a novel genetic cause of RCM
occurring in a conserved domain which causes dysfunction of
calcium-based regulation of cardiac contraction and likely
yields significant myocardial diastolic dysfunction. This variant,
when compared with control cohorts, has a high likelihood of
producing a malignant phenotype. Furthermore, this work
demonstrates the power of using in vitro biochemical studies as
well as computational modeling to support disease causality.
Acknowledgments
We acknowledge Lina Greenberg for technical support in generating
and purifying the mutant proteins.
Sources of Funding
Ezekian is supported by the NIH Clinical and Translational
Science Award (UL1TR00255). Clippinger is supported by the
NIH (T32EB018266). Greenberg is supported by the NIH
(R01HL141086), the March of Dimes Foundation (FY18-BOC-
430198), and the Children’s Discovery Institute of Washington
University and St. Louis Children’s Hospital (PM-LI-2019-829).
Landstrom is supported by the Phoebe Muzzy-McCrae
Foundation and Duke University School of Medicine.
Disclosures
None.
References
1. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg
O, Kuhl U, Maisch B, McKenna WJ, Monserrat L, Pankuweit S, Rapezzi C,
Seferovic P, Tavazzi L, Keren A. Classification of the cardiomyopathies:
a position statement from the European Society Of Cardiology Working
Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270–
276.
2. Anderson HN, Cetta F, Driscoll DJ, Olson TM, Ackerman MJ, Johnson JN.
Idiopathic restrictive cardiomyopathy in children and young adults. Am J
Cardiol. 2018;121:1266–1270.
3. Cetta F, O’Leary PW, Seward JB, Driscoll DJ. Idiopathic restrictive cardiomy-
opathy in childhood: diagnostic features and clinical course. Mayo Clin Proc.
1995;70:634–640.
4. Harvey PA, Leinwand LA. The cell biology of disease: cellular mechanisms of
cardiomyopathy. J Cell Biol. 2011;194:355–365.
5. Maron BJ, Haas TS, Ahluwalia A, Murphy CJ, Garberich RF. Demographics and
epidemiology of sudden deaths in young competitive athletes: from the United
States National Registry. Am J Med. 2016;129:1170–1177.
6. Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of
clinically diagnosed hypertrophic cardiomyopathy in the United States. Am J
Cardiol. 2016;117:1651–1654.
7. Van Driest SL, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ. Sarcomeric
genotyping in hypertrophic cardiomyopathy. Mayo Clin Proc. 2005;80:463–
469.
8. Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopathies. N Engl J Med.
2011;364:1643–1656.
9. Sabater-Molina M, Perez-Sanchez I, Hernandez Del Rincon JP, Gimeno JR.
Genetics of hypertrophic cardiomyopathy: a review of current state. Clin
Genet. 2018;93:3–14.
10. Wang L, Kim K, Parikh S, Cadar AG, Bersell KR, He H, Pinto JR, Kryshtal DO,
Knollmann BC. Hypertrophic cardiomyopathy-linked mutation in troponin T
causes myofibrillar disarray and pro-arrhythmic action potential changes in
human iPSC cardiomyocytes. J Mol Cell Cardiol. 2018;114:320–327.
11. Wang L, Kryshtal DO, Kim K, Parikh S, Cadar AG, Bersell KR, He H, Pinto JR,
Knollmann BC. Myofilament calcium-buffering dependent action potential
triangulation in human-induced pluripotent stem cell model of hypertrophic
cardiomyopathy. J Am Coll Cardiol. 2017;70:2600–2602.
12. Baudenbacher F, Schober T, Renato Pinto J, Sidorov VY, Hilliard F, Solaro RJ,
Potter JD, Knollmann BC. Myofilament Ca2+ sensitization causes susceptibility
to cardiac arrhythmia in mice. J Clin Invest. 2008;118:3893–3903.
13. Varnava A, Baboonian C, Davison F, de Cruz L, Elliott PM, Davies MJ, McKenna
WJ. A new mutation of the cardiac troponin T gene causing familial
hypertrophic cardiomyopathy without left ventricular hypertrophy. Heart.
1999;82:621–624.
14. Parvatiyar MS, Pinto JR. Pathogenesis associated with a restrictive cardiomy-
opathy mutant in cardiac troponin T is due to reduced protein stability and
greatly increased myofilament Ca2+ sensitivity. Biochim Biophys Acta.
2015;1850:365–372.
15. Kaski JP, Syrris P, Burch M, Tome-Esteban MT, Fenton M, Christiansen M,
Andersen PS, Sebire N, Ashworth M, Deanfield JE, McKenna WJ, Elliott PM.
Idiopathic restrictive cardiomyopathy in children is caused by mutations in
cardiac sarcomere protein genes. Heart. 2008;94:1478–1484.
16. Gallego-Delgado M, Delgado JF, Brossa-Loidi V, Palomo J, Marzoa-Rivas R,
Perez-Villa F, Salazar-Mendiguchia J, Ruiz-Cano MJ, Gonzalez-Lopez E, Padron-
Barthe L, Bornstein B, Alonso-Pulpon L, Garcia-Pavia P. Idiopathic restrictive
cardiomyopathy is primarily a genetic disease. J Am Coll Cardiol.
2016;67:3021–3023.
17. Menon SC, Michels VV, Pellikka PA, Ballew JD, Karst ML, Herron KJ, Nelson
SM, Rodeheffer RJ, Olson TM. Cardiac troponin T mutation in familial
cardiomyopathy with variable remodeling and restrictive physiology. Clin
Genet. 2008;74:445–454.
18. Lu QW, Morimoto S, Harada K, Du CK, Takahashi-Yanaga F, Miwa Y, Sasaguri T,
Ohtsuki I. Cardiac troponin T mutation R141W found in dilated cardiomyopa-
thy stabilizes the troponin T-tropomyosin interaction and causes a Ca2+
desensitization. J Mol Cell Cardiol. 2003;35:1421–1427.
19. Mickelson AV, Chandra M. Hypertrophic cardiomyopathy mutation in cardiac
troponin T (R95H) attenuates length-dependent activation in guinea pig
cardiac muscle fibers. Am J Physiol Heart Circ Physiol. 2017;313:H1180–
H1189.
20. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O’Donnell-
Luria AH, Ware JS, Hill AJ, Cummings BB, Tukiainen T, Birnbaum DP, Kosmicki
JA, Duncan LE, Estrada K, Zhao F, Zou J, Pierce-Hoffman E, Berghout J, Cooper
DN, Deflaux N, DePristo M, Do R, Flannick J, Fromer M, Gauthier L, Goldstein J,
Gupta N, Howrigan D, Kiezun A, Kurki MI, Moonshine AL, Natarajan P, Orozco
L, Peloso GM, Poplin R, Rivas MA, Ruano-Rubio V, Rose SA, Ruderfer DM,
Shakir K, Stenson PD, Stevens C, Thomas BP, Tiao G, Tusie-Luna MT, Weisburd
B, Won HH, Yu D, Altshuler DM, Ardissino D, Boehnke M, Danesh J, Donnelly S,
Elosua R, Florez JC, Gabriel SB, Getz G, Glatt SJ, Hultman CM, Kathiresan S,
Laakso M, McCarroll S, McCarthy MI, McGovern D, McPherson R, Neale BM,
Palotie A, Purcell SM, Saleheen D, Scharf JM, Sklar P, Sullivan PF, Tuomilehto J,
Tsuang MT, Watkins HC, Wilson JG, Daly MJ, MacArthur DG; Exome
Aggregation Consortium. Analysis of protein-coding genetic variation in
60,706 humans. Nature. 2016;536:285–291.
21. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde
M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality
Assurance Committee. Standards and guidelines for the interpretation of
DOI: 10.1161/JAHA.119.015111 Journal of the American Heart Association 10
TNNT2-R94C in Restrictive Cardiomyopathy Ezekian et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on A
pril 3, 2020
sequence variants: a joint consensus recommendation of the American
College of Medical Genetics and Genomics and the Association for Molecular
Pathology. Genet Med. 2015;17:405–424.
22. Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, Gu B, Hart J,
Hoffman D, Jang W, Karapetyan K, Katz K, Liu C, Maddipatla Z, Malheiro A,
McDaniel K, Ovetsky M, Riley G, Zhou G, Holmes JB, Kattman BL, Maglott DR.
ClinVar: improving access to variant interpretations and supporting evidence.
Nucleic Acids Res. 2018;46:D1062–D1067.
23. NCBI. Troponin T, cardiac muscle isoform 2 [Homo sapiens]. 2019:NCBI
Reference Sequence: NP_001001430.1. Bethesda MD: National Center for
Biotechnology Information.
24. Corpet F. Multiple sequence alignment with heirarchical clustering. Nucleic
Acids Res. 1988;16:10881–10890.
25. Corpet F, Gouzy J, Kahn D. Browsing protein families via the ‘Rich Family
Description’ format. Bioinformatics. 1999;15:1020–1027.
26. Dahlquist KD, Salomonis N, Vranizan K, Lawlor SC, Conklin BR. GenMAPP, a
new tool for viewing and analyzing microarray data on biological pathways. Nat
Genet. 2002;31:19–20.
27. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P,
Kondrashov AS, Sunyaev SR. A method and server for predicting damaging
missense mutations. Nat Methods. 2010;7:248–249.
28. Bendl J, Stourac J, Salanda O, Pavelka A, Wieben ED, Zendulka J, Brezovsky J,
Damborsky J. PredictSNP: robust and accurate consensus classifier for
prediction of disease-related mutations. PLoS Comput Biol. 2014;10:
e1003440.
29. Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server:
predicting effects of amino acid substitutions on proteins. Nucleic Acids Res.
2012;40:W452–W457.
30. Korf I. Gene finding in novel genomes. BMC Bioinformatics. 2004;5:59.
31. Mi H, Muruganujan A, Ebert D, Huang X, Thomas PD. PANTHER version 14:
more genomes, a new PANTHER GO-slim and improvements in enrichment
analysis tools. Nucleic Acids Res. 2019;47:D419–D426.
32. Barrick SK, Clippinger SR, Greenberg L, Greenberg MJ. Computational tool to
study perturbations in muscle regulation and its application to heart disease.
Biophys J. 2019;116:2246–2252.
33. Clippinger SR, Cloonan PE, Greenberg L, Ernst M, Stump WT, Greenberg MJ.
Disrupted mechanobiology links the molecular and cellular phenotypes in
familial dilated cardiomyopathy. Proc Natl Acad Sci USA. 2019;116:17831–
17840.
34. Greenberg MJ, Shuman H, Ostap EM. Inherent force-dependent properties of
beta-cardiac myosin contribute to the force-velocity relationship of cardiac
muscle. Biophys J. 2014;107:L41–L44.
35. Eads TM, Thomas DD, Austin RH. Microsecond rotational motions of eosin-
labeled myosin measured by time-resolved anisotropy of absorption and
phosphorescence. J Mol Biol. 1984;179:55–81.
36. Margossian SS, Lowey S. Preparation of myosin and its subfragments from
rabbit skeletal muscle. Methods Enzymol. 1982;85(Pt B):55–71.
37. Spudich JA, Watt S. The regulation of rabbit skeletal muscle contraction. I.
Biochemical studies of the interaction of the tropomyosin-troponin complex
with actin and the proteolytic fragments of myosin. J Biol Chem.
1971;246:4866–4871.
38. Pollard TD. Purification of a high molecular weight actin filament gelation
protein from Acanthamoeba that shares antigenic determinants with verte-
brate spectrins. J Cell Biol. 1984;99:1970–1980.
39. Greenberg MJ, Lin T, Goldman YE, Shuman H, Ostap EM. Myosin IC generates
power over a range of loads via a new tension-sensing mechanism. Proc Natl
Acad Sci USA. 2012;109:E2433–E2440.
40. Hitchcock-DeGregori SE, Heald RW. Altered actin and troponin binding of
amino-terminal variants of chicken striated muscle alpha-tropomyosin
expressed in Escherichia coli. J Biol Chem. 1987;262:9730–9735.
41. Pan S, Sommese RF, Sallam KI, Nag S, Sutton S, Miller SM, Spudich JA, Ruppel
KM, Ashley EA. Establishing disease causality for a novel gene variant in
familial dilated cardiomyopathy using a functional in-vitro assay of regulated
thin filaments and human cardiac myosin. BMC Med Genet. 2015;16:97.
42. McIntosh BB, Holzbaur EL, Ostap EM. Control of the initiation and termination
of kinesin-1-driven transport by myosin-Ic and nonmuscle tropomyosin. Curr
Biol. 2015;25:523–529.
43. Kozaili JM, Leek D, Tobacman LS. Dual regulatory functions of the thin filament
revealed by replacement of the troponin I inhibitory peptide with a linker. J Biol
Chem. 2010;285:38034–38041.
44. McKillop DF, Geeves MA. Regulation of the interaction between actin and
myosin subfragment 1: evidence for three states of the thin filament. Biophys
J. 1993;65:693–701.
45. Maytum R, Westerdorf B, Jaquet K, Geeves MA. Differential regulation of the
actomyosin interaction by skeletal and cardiac troponin isoforms. J Biol Chem.
2003;278:6696–6701.
46. Campbell SG, Lionetti FV, Campbell KS, McCulloch AD. Coupling of
adjacent tropomyosins enhances cross-bridge-mediated cooperative activa-
tion in a Markov model of the cardiac thin filament. Biophys J.
2010;98:2254–2264.
47. Colan S. Normal echocardiographic values for cardiovascular structures. In:
Lai W, Cohen M, Geva T, Mertens L, eds. Echocardiography in Pediatric and
Congenital Heart Disease. West Sussex, UK: Wiley-Blackwell; 2009:765–
785.
48. Molina DK, Pinneri K, Stash JA, Li L, Vance K, Cross C. Organ weight
reference ranges for ages 0 to 12 years. Am J Forensic Med Pathol.
2019;40:318–328.
49. Guatimosim S, Dilly K, Santana LF, Saleet Jafri M, Sobie EA, Lederer WJ. Local
Ca(2+) signaling and EC coupling in heart: Ca(2+) sparks and the regulation of
the [Ca(2+)](i) transient. J Mol Cell Cardiol. 2002;34:941–950.
50. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415:198–205.
51. Landstrom AP, Boczek NJ, Ye D, Miyake CY, De la Uz CM, Allen HD, Ackerman
MJ, Kim JJ. Novel long QT syndrome-associated missense mutation, L762F, in
CACNA1C-encoded L-type calcium channel imparts a slower inactivation tau
and increased sustained and window current. Int J Cardiol. 2016;220:290–
298.
52. Connell PS, Jeewa A, Kearney DL, Tunuguntla H, Denfield SW, Allen HD,
Landstrom AP. A 14-year-old in heart failure with multiple cardiomyopathy
variants illustrates a role for signal-to-noise analysis in gene test re-
interpretation. Clin Case Rep. 2019;7:211–217.
53. Ho CY, Charron P, Richard P, Girolami F, Van Spaendonck-Zwarts KY, Pinto Y.
Genetic advances in sarcomeric cardiomyopathies: state of the art. Cardiovasc
Res. 2015;105:397–408.
54. Rindler TN, Hinton RB, Salomonis N, Ware SM. Molecular characterization of
pediatric restrictive cardiomyopathy from integrative genomics. Sci Rep.
2017;7:39276.
55. Lopes LR, Syrris P, Guttmann OP, O’Mahony C, Tang HC, Dalageorgou C,
Jenkins S, Hubank M, Monserrat L, McKenna WJ, Plagnol V, Elliott PM. Novel
genotype-phenotype associations demonstrated by high-throughput sequenc-
ing in patients with hypertrophic cardiomyopathy. Heart. 2015;101:294–301.
56. Berge KE, Leren TP. Genetics of hypertrophic cardiomyopathy in Norway. Clin
Genet. 2014;86:355–360.
57. Liu W, Liu W, Hu D, Zhu T, Ma Z, Yang J, Xie W, Li C, Li L, Yang J, Li T, Bian H,
Tong Q. Mutation spectrum in a large cohort of unrelated Chinese patients
with hypertrophic cardiomyopathy. Am J Cardiol. 2013;112:585–589.
58. Otsuka H, Arimura T, Abe T, Kawai H, Aizawa Y, Kubo T, Kitaoka H, Nakamura
H, Nakamura K, Okamoto H, Ichida F, Ayusawa M, Nunoda S, Isobe M,
Matsuzaki M, Doi YL, Fukuda K, Sasaoka T, Izumi T, Ashizawa N, Kimura A.
Prevalence and distribution of sarcomeric gene mutations in Japanese patients
with familial hypertrophic cardiomyopathy. Circ J. 2012;76:453-461.
59. Chandra M, Tschirgi ML, Tardiff JC. Increase in tension-dependent ATP
consumption induced by cardiac troponin T mutation. Am J Physiol Heart Circ
Physiol. 2005;289:H2112–H2119.
60. Ford SJ, Mamidi R, Jimenez J, Tardiff JC, Chandra M. Effects of R92 mutations
in mouse cardiac troponin T are influenced by changes in myosin heavy chain
isoform. J Mol Cell Cardiol. 2012;53:542–551.
61. Robinson P, Mirza M, Knott A, Abdulrazzak H, Willott R, Marston S, Watkins H,
Redwood C. Alterations in thin filament regulation induced by a human cardiac
troponin T mutant that causes dilated cardiomyopathy are distinct from those
induced by troponin T mutants that cause hypertrophic cardiomyopathy. J Biol
Chem. 2002;277:40710–40716.
62. Szczesna D, Zhang R, Zhao J, Jones M, Guzman G, Potter JD. Altered regulation
of cardiac muscle contraction by troponin T mutations that cause familial
hypertrophic cardiomyopathy. J Biol Chem. 2000;275:624–630.
63. Tobacman LS, Lin D, Butters C, Landis C, Back N, Pavlov D, Homsher E.
Functional consequences of troponin T mutations found in hypertrophic
cardiomyopathy. J Biol Chem. 1999;274:28363–28370.
64. Williams MR, Lehman SJ, Tardiff JC, Schwartz SD. Atomic resolution probe for
allostery in the regulatory thin filament. Proc Natl Acad Sci USA.
2016;113:3257–3262.
65. Gangadharan B, Sunitha MS, Mukherjee S, Chowdhury RR, Haque F, Sekar N,
Sowdhamini R, Spudich JA, Mercer JA. Molecular mechanisms and structural
features of cardiomyopathy-causing troponin T mutants in the tropomyosin
overlap region. Proc Natl Acad Sci USA. 2017;114:11115–11120.
66. Palm T, Graboski S, Hitchcock-DeGregori SE, Greenfield NJ. Disease-causing
mutations in cardiac troponin T: identification of a critical tropomyosin-binding
region. Biophys J. 2001;81:2827–2837.
DOI: 10.1161/JAHA.119.015111 Journal of the American Heart Association 11
TNNT2-R94C in Restrictive Cardiomyopathy Ezekian et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on A
pril 3, 2020
 
 
 
 
 
 
 
 
SUPPLEMENTAL MATERIAL 
 
D
ow
nloaded from
 http://ahajournals.org by on A
pril 3, 2020
 
Table S1. Clinical and genetic information for the multi-generational family. 
Individual Age 
(years) 
Sex Status TNNT2-R94C 
Status 
Cardiovascular Phenotype 
I.1 78 M Deceased Unknown  
I.2 83 F Deceased Unknown  
I.3 81 M Deceased Unknown  
I.4 83 F Alive Unknown  
II.1 59 M Alive -/- Atrial fibrillation 
II.2 60 F Alive -/-  
II.3 57 M Deceased Unknown  
II.4 Unknown F Alive Unknown  
III.1 33 M Alive Unknown  
III.2 31 F Alive -/- Supraventricular tachycardia 
III.3 35 M Alive +/- Ventricular tachycardia 
III.4 36 F Alive -/-  
IV.1 4 M Alive -/-  
IV.2 4 M Deceased +/- Hypertrophic cardiomyopathy with 
restrictive features, sudden cardiac 
arrest 
IV.3 2 F Deceased +/- Restrictive cardiomyopathy with mild 
hypertrophy, sudden cardiac arrest 
IV.4 Fetus Unknown Deceased Unknown First trimester fetal death 
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